The MiniMed™ 780G system (780G) received Conformité Européenne mark in June 2020 and was, recently, approved by the U.S. Food and Drug Administration (April 2023). Clinical trials and real-world analyses have demonstrated MiniMed™ 780G system safety and effectiveness and that glycemic outcomes (i.e., time in range) improve with recommended settings use. In this publication, we will explain the iterative development of the 780G algorithm and how this technology has simplified diabetes management.
Get full access to this article
View all access options for this article.
References
1.
SteilGM, PanteleonAE, RebrinK. Closed-loop insulin delivery—The path to physiological glucose control. Adv Drug Del Rev, 2004; 56:125–144.
2.
KanderianSS, WeinzimerSA, SteilGM. The identifiable virtual patient model: Comparison of simulation and clinical closed-loop study results. J Diabetes Sci Technol, 2012; 6:371–379.
3.
LoutseikoM, VoskanyanG, KeenanDB, et al.Closed-loop insulin delivery utilizing pole placement to compensate for delays in subcutaneous insulin delivery. J Diabetes Sci Technol, 2011; 5:1342–1351.
4.
GargS, BrazgRL, BaileyTS, et al.Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: The in-clinic ASPIRE study. Diabetes Technol Ther, 2012; 14:205–209.
5.
BuckinghamBA, CameronF, CalhounP, et al.Outpatient safety assessment of an in-home predictive low-glucose suspend system with type 1 diabetes subjects at elevated risk of nocturnal hypoglycemia. Diabetes Technol Ther, 2013; 15:622–627.
6.
PehlingG, TessariP, GerichJE, et al.Abnormal meal carbohydrate disposition in insulin-dependent diabetes. Relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy. J Clin Invest, 1984; 74:985–991.
7.
RorsmanP, EliassonL, RenströmE, et al.The cell physiology of biphasic insulin secretion. Physiology, 2000; 15:72–77.
8.
GoodwinGC, MedioliAM, CarrascoDS, et al.A fundamental control limitation for linear positive systems with application to type 1 diabetes treatment. Automatica, 2015; 55:73–77.
9.
Da SilvaJ, BosiE, JendleJ, et al.Real-world performance of the MiniMed 670G system in Europe. Diabetes Obes Metab, 2021; 23:1942–1949.
10.
AgrawalP, StoneM, GopalakrishnanS, et al.Real-world data from the Minimed™ 670G system commercial launch-the first 1,052 patients using the system for three months. Diabetes, 2018; 67:A259–A260.
11.
GargSK, WeinzimerSA, TamborlaneWV, et al.Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2017; 19:155–163.
12.
HoltRIG, DeVriesJH, Hess-FischlA, et al.The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2021; 44:2589–2625.
13.
BergetC, AkturkHK, MesserLH, et al.Real-world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed-loop use. Diabetes Obes Metab, 2021; 23:2048–2057.
14.
GrosmanB, WuD, MillerD, et al.Sensor-augmented pump-based customized mathematical model for type 1 diabetes. Diabetes Technol Ther, 2018; 20:207–221.
15.
CobryEC, VigersT, BergetC, et al.Frequency and causes of nocturnal alarms in youth and young adults with type 1 diabetes using a first-generation hybrid closed-loop system. Diabetes Spectr, 2023. [Epub ahead of print]; doi: 10.2337/ds23-0003
16.
DuffusSH, Ta'aniZA, SlaughterJC, et al.Increased proportion of time in hybrid closed-loop “Auto Mode” is associated with improved glycaemic control for adolescent and young patients with adult type 1 diabetes using the MiniMed 670G insulin pump. Diabetes Obes Metab, 2020; 22:688–693.
17.
CarlsonAL, SherrJL, ShulmanDI, et al.Safety and glycemic outcomes during the MiniMed advanced hybrid closed-loop system pivotal trial in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2022; 24:178–189.
18.
GrassiB, GomezAM, CalliariLE, et al.Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system. Diabetes Obes Metab, 2023; 25:1688–1697.
19.
SilvaJD, LeporeG, BattelinoT, et al.Real-world performance of the MiniMed 780G system: First report of outcomes from 4120 users. Diabetes Technol Ther, 2022; 24:113–119.
20.
PihokerC, ShulmanDI, ForlenzaGP, et al.Safety and glycemic outcomes during the MiniMed(TM) advanced hybrid closed-loop system pivotal trial in children and adolescents with type 1 diabetes. Diabetes Technol Ther, 2023; 25:755–764.
21.
ArrietaA, BattelinoT, ScaramuzzaAE, et al.Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users. Diabetes Obes Metab, 2022; 24:1370–1379.
ShalitR, MinskyN, Laron-HirshM, et al.Unannounced meal challenges using an advanced hybrid closed-loop system. Diabetes Technol Ther, 2023; 25:579–588.
24.
PetrovskiG, CampbellJ, PashaM, et al.Simplified meal announcement versus precise carbohydrate counting in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed loop system: A randomized controlled trial comparing glucose control. Diabetes Care, 2023; 46:544–550.
25.
CorderoTL, DaiZ, ArrietaA, et al.Glycemic outcomes during early use of the MiniMed 780G advanced hybrid closed-loop system with Guardian 4 sensor. Diabetes Technol Ther, 2023; 25:652–658.
26.
CastanedaJ, MathieuC, AanstootHJ, et al.Predictors of time in target glucose range in real-world users of the MiniMed 780G system. Diabetes Obes Metab, 2022; 24:2212–2221.
